Company will develop a cell-based assay for discovery projects and carry out compound management.

Galapagos entered into a €41. million, or $5.4 million, drug discovery and compound-management agreement with Dart Neuroscience (DNS).

Galapagos service division, BioFocus DPI, will develop a cell-based assay for DNS’ drug discovery programs for brain disorders. It will perform high-throughput screening and hit expansion using BioFocus DPI’s compound collections.  The three-year contract also calls for certain compound-management projects.

 “This collaboration maximizes several key BioFocus DPI strengths: assay development and high-throughput screening as well as compound libraries and compound management,” points out Onno van de Stolpe, CEO of Galapagos.

Previous articleGene Mutation Alters Circadian Rhythm and Elevates Diabetes Risk
Next articleMedivir Receives a $3.3M Milestone Fee from Tibotec in HCV Collaboration